RxDoctor Payments DataLook up a doctor →

Tyson Parker, PA

Physician Assistant · Idaho Falls, IDNPI 1295921484

Payments from drug & device makers

$9,620in general payments, 2019–2025

Across 599 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$758
  • Novo Nordisk$421
  • Amgen$403
  • Boehringer Ingelheim$395
  • Astellas Pharma US Inc$351
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,614100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie141$2,435
Lilly USA, LLC75$758
Novo Nordisk36$421
Amgen(2 entities)29$403
Boehringer Ingelheim22$395
Astellas Pharma US Inc17$351
AstraZeneca11$334
Axsome Therapeutics, Inc.22$327
Otsuka America Pharmaceutical, Inc.22$319
Vanda Pharmaceuticals Inc.10$294
GSK18$257
Antares Pharma, Inc.13$234
Novartis12$203
Lundbeck LLC7$160
Teva Pharmaceuticals USA, Inc.10$160
Bayer10$148
Boston Scientific8$144
Merck8$134
Biocryst US Sales Co., LLC5$111
CSL Behring4$104
Pfizer7$101
Nestle Healthcare Nutrition Inc.5$101
Phathom Pharmaceuticals, Inc.9$98
Shield Therapeutics Inc5$95
Dexcom, Inc.4$87
Corium, LLC9$82
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$81
Corcept Therapeutics4$79
Amarin Pharma, Inc.5$79
Genentech USA, Inc.5$75
Johnson & Johnson4$66
Averitas Pharma Inc.2$65
Ironshore Pharmaceuticals Inc.3$57
Neurocrine Biosciences, Inc.3$57
Aimmune Therapeutics, Inc.3$56
Ionis Pharmaceuticals, Inc.2$49
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$44
Takeda Pharmaceuticals U.S.A., Inc.3$43
Esperion Therapeutics, Inc.3$42
Mylan Specialty L.p.2$40
Sanofi Pasteur Inc.2$38
Alnylam Pharmaceuticals Inc.2$37
Supernus Pharmaceuticals, Inc.2$37
Neurelis, Inc.2$34
Sunovion Pharmaceuticals Inc.2$31
Acadia Pharmaceuticals Inc2$30
Impel Pharmaceuticals Inc.2$28
Sanofi-aventis U.S. LLC2$23
Abbott1$23
BD1$22
Sumitomo Pharma America, Inc.1$19
Medtronic1$18
Ultragenyx Pharmaceutical Inc.1$18
Ipsen Biopharmaceuticals, Inc1$18
Seqirus USA Inc1$18
Edwards Lifesciences1$16
Regeneron Healthcare Solutions, Inc.1$15
Pharming Healthcare, Inc.1$15
Xeris Pharmaceuticals, Inc.1$15
Therapeuticsmd, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,620 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$42,070
Medicare patients
181
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$67,293
TrulicityDulaglutide42$46,615
MounjaroTirzepatide39$40,814
FarxigaDapagliflozin Propanediol34$31,877
EliquisApixaban34$30,830
JardianceEmpagliflozin32$28,090
ViberziEluxadoline12$19,860
Synjardy XrEmpagliflozin/Metformin Hcl20$14,632
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,451
Tresiba Flextouch U-200Insulin Degludec20$9,054
LinzessLinaclotide12$6,569
MyrbetriqMirabegron12$5,365
Humalog Kwikpen U-200Insulin Lispro18$5,265
Atomoxetine Hcl24$4,326
Celecoxib37$4,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$758$87,42881 claims
Novo NordiskOzempic$421$67,29360 claims
Boehringer IngelheimJardiance, Synjardy Xr$395$42,72252 claims
AstraZenecaFarxiga$334$31,87734 claims
PfizerEliquis$101$30,83034 claims
AbbVieViberzi, Linzess$2,435$26,42924 claims
GSKTrelegy Ellipta$257$12,45112 claims
Astellas Pharma US IncMyrbetriq$351$5,36512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →